Back to search
Moderate to Severe Plaque Psoriasis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Moderate to Severe Plaque Psoriasis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Moderate to Severe Plaque Psoriasis trials you may qualify forThe primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in childr…
The main aim of this study is to see how well the medicine zasocitinib works, how safe it is, and how children and teenagers aged 4 to under 18 with moderate-to…
A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.
The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to sever…
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants w…
The purpose of this study is to monitor the long-term safety of ustekinumab in pediatric participants (6 years to 17 years of age at the time of inclusion) with…
The goal of this trial is to assess whether the efficacy of CMAB015 is similar to that of Secukinumab in patients with moderate-severe chronic plaque psoriasis.…
The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe…